Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
Mönnikes H, Schwan T, van Rensburg C, Straszak A, Theek C, Sander P, Lühmann R. Mönnikes H, et al. Among authors: van rensburg c. Aliment Pharmacol Ther. 2012 Jun;35(11):1279-89. doi: 10.1111/j.1365-2036.2012.05085.x. Epub 2012 Apr 8. Aliment Pharmacol Ther. 2012. PMID: 22486552 Free article. Clinical Trial.
Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.
Mönnikes H, Schwan T, van Rensburg C, Straszak A, Theek C, Lühmann R, Sander P, Tholen A. Mönnikes H, et al. Among authors: van rensburg c. BMC Gastroenterol. 2013 Oct 1;13:145. doi: 10.1186/1471-230X-13-145. BMC Gastroenterol. 2013. PMID: 24083350 Free PMC article. Clinical Trial.
Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: are G-protein β3 subunit genotype, Helicobacter pylori status, and environmental factors response modifiers?
Holtmann G, van Rensburg C, Schwan T, Sander P, Siffert W. Holtmann G, et al. Among authors: van rensburg c. Digestion. 2011;84(4):289-98. doi: 10.1159/000331468. Epub 2011 Oct 26. Digestion. 2011. PMID: 22041889 Clinical Trial.
Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.
Van Rensburg CJ, Honiball PJ, Van Zyl JH, Grundling HD, Eloff FP, Spies SK, Simjee AE, Theron I, Fischer R, Louw JA. Van Rensburg CJ, et al. Among authors: van zyl jh. Aliment Pharmacol Ther. 1999 Aug;13(8):1023-8. doi: 10.1046/j.1365-2036.1999.00573.x. Aliment Pharmacol Ther. 1999. PMID: 10468676 Free article. Clinical Trial.
Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial.
van Rensburg C, Barkun AN, Racz I, Fedorak R, Bornman PC, Beglinger C, Balanzó J, Devière J, Kupcinskas L, Luehmann R, Doerfler H, Schäfer-Preuss S. van Rensburg C, et al. Aliment Pharmacol Ther. 2009 Mar 1;29(5):497-507. doi: 10.1111/j.1365-2036.2008.03904.x. Epub 2008 Nov 27. Aliment Pharmacol Ther. 2009. PMID: 19053987 Free article. Clinical Trial.
177 results